Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Hyperlipoproteinemia Type II 1Endometrial Neoplasms 1

Interventions

Docetaxel 171Radiotherapy 144Magnetic Resonance Spectroscopy 142Leuprolide 112Prednisone 108enzalutamide 102Radiosurgery 101Abiraterone Acetate 94Androgen Antagonists 91Goserelin 83bicalutamide 81gallium 68 PSMA-11 70Surveys and Questionnaires 63apalutamide 57Specimen Handling 56acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 55Radiation 47Gonadotropin-Releasing Hormone 45Standard of Care 44Biopsy 44Brachytherapy 42Radiotherapy, Intensity-Modulated 40Blood Specimen Collection 40darolutamide 39abiraterone 39cabazitaxel 35Exercise 35Carboplatin 33Pluvicto 32Triptorelin Pamoate 31

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Prostatic Neoplasms × Ezetimibe × Clear all
NCT06437574 2026-03-11

Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer

Cedars-Sinai Medical Center

Phase 2 Recruiting
140 enrolled
Genitourinary

Prostatic Neoplasms

NCT02534376 2023-02-22

Cellular Effect of Cholesterol-Lowering Prior to Prostate Removal

Cedars-Sinai Medical Center

Phase EARLY_PHASE1 Completed
63 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡